DHEA (Dehydroepiandrosterone)
EmergingEndogenous adrenal precursor to testosterone and estradiol. | Supplement · Capsule
Aliases (4)
▸Brand options3 known
StatusOTC supplement (US); Rx-only / banned (EU, Canada, Australia); WADA-banned in-competition and out-of-competition
▸ Overview TL;DR
Endogenous adrenal precursor to testosterone and estradiol. Levels peak around age 20-25 then decline ~2%/year — supplementation has real signal in deficient older adults but is hormonally redundant and HPG-perturbing in a 20yo at peak production. Skip until bloodwork proves otherwise.
▸ Mechanism of action
DHEA is produced by the adrenal cortex (zona reticularis) and is the most abundant circulating steroid in humans. It serves three overlapping roles:
- Sex-steroid precursor. DHEA → androstenedione (via 3β-HSD) → testosterone (via 17β-HSD), and androstenedione → estrone → estradiol (via aromatase). Tissue-specific enzyme expression determines whether DHEA flows toward androgens or estrogens — adipose tissue and breast/prostate epithelium are aromatase-rich, so peripheral conversion can favor estradiol.
- Weak direct receptor activity. DHEA itself is a weak agonist at androgen and estrogen receptors and a weak σ1 receptor agonist.
- Neurosteroid. DHEA and its sulfate (DHEA-S) modulate GABA-A (negative allosteric — pro-arousal) and NMDA (positive allosteric — pro-cognitive/excitatory). This underlies the "mood/cognition" claims.
Endogenous DHEA-S follows a clear lifecourse: rises sharply at adrenarche (age 6-8), peaks around age 20-25, then declines ~2%/year. By age 70 levels are ~10-20% of peak — this is "adrenopause." Supplementation in deficient older adults can restore DHEA-S, testosterone, and estradiol toward youthful ranges; supplementation in someone already at peak just adds substrate to a saturated system or pushes downstream conversion (more aromatization to E2).
▸ Pharmacokinetics No data
▸Quality indicators4 checks
▸ What to expect Generic
- 1Week 1Baseline tolerability. Most chronic-use supplements have no acute signal.
- 2Week 2-4Subtle baseline shift — sleep quality, mood, recovery markers.
- 3Week 4-8Reach steady state. Re-assess subjective + objective markers.
- 4Month 3+Long-term maintenance dose if benefit confirmed; otherwise stop.
▸ Side effects + safety
Common (>10% users, dose-dependent):
- Acne, oily skin (peripheral conversion to androgens)
- Hair shedding / accelerated androgenetic alopecia in predisposed men
- Mild emotional reactivity / irritability
Less common (1-10%):
- Gynecomastia or nipple sensitivity (peripheral aromatization to E2, especially in higher BMI / aromatase-rich tissue)
- Voice deepening / hirsutism (women)
- Sleep disturbance
- Mild HPG axis suppression (LH/FSH downregulation as exogenous androgens/estrogens feed back on hypothalamus)
Rare-serious (<1% but worth knowing):
- Theoretical hormone-sensitive cancer risk (breast, prostate, ovarian). No causal trials but mechanistically plausible — DHEA increases circulating estradiol and testosterone in tissue. Most clinicians counsel avoidance with personal/family history of these cancers.
- Hepatotoxicity at very high doses (>200mg/day, rare).
- Mood destabilization in bipolar-spectrum users.
Specific watch periods: First 4-8 weeks for acne/skin/mood changes; if used long-term, reassess hormone panel every 3 months.
▸References6 sources
Arlt W et al. "Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency." NEJM 1999;341(14):1013-1020. **PMID: 10502590**
1999Cleanest deficiency-replacement RCT; n=24 women with adrenal insufficiency, 50 mg/day DHEA × 4 months crossover; restored DHEA-S, modest …
Villareal DT, Holloszy JO. "Effect of DHEA on Abdominal Fat and Insulin Action in Elderly Women and Men: A Randomized Controlled Trial." JAMA 2004;292(18):2243-2248. **PMID: 15536111**
2004n=56 (28M / 28F, age 65-78), 50 mg/day × 6 months; visceral fat −13 cm² vs +3 cm² (p=0.001), subcutaneous fat −13 cm² vs +2 cm² (p=0.003)…
Nair KS et al. "DHEA in Elderly Women and DHEA or Testosterone in Elderly Men." NEJM 2006;355(16):1647-1659. **PMID: 17050889**
2006Mayo Clinic 2-year RCT, n=87 men + 57 women age 60+; 75 mg/day men, 50 mg/day women. Negative trial: no improvement in body composition, …
Orentreich N, Brind JL, Rizer RL, Vogelman JH. "Age Changes and Sex Differences in Serum Dehydroepiandrosterone Sulfate Concentrations Throughout Adulthood in Men." J Clin Endocrinol Metab 1984;59(3):551-555. **PMID: 6235241**
1984Foundational lifecourse data establishing the ~2%/year decline pattern; the most-cited DHEA-S age-trajectory paper.
Villareal DT, Holloszy JO. "DHEA Enhances Effects of Weight Training on Muscle Mass and Strength in Elderly Women and Men." Am J Physiol Endocrinol Metab 2006;291(5):E1003-E1008. **PMID: 16787962**
2006Follow-up to JAMA 2004; n=56, 50 mg/day + weight training × 6 months. Augmented muscle mass + strength gains over training alone in older…